3,4-dihydroxybenzohydroxamic acid has been researched along with Disease Exacerbation in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined a new series of RRIs, 3,4-dihydroxybenzohydroxamic acid (Didox) and 3,4,5-trihydroxybenzohydroxamidoxime (Trimidox) for their ability to alter disease progression in murine acquired immunodeficiency syndrome (MAIDS), both alone and in combination with 2',3'-dideoxyinosine (ddI)." | 1.30 | Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS). ( Birch, NJ; Elford, HL; Gallicchio, VS; Hughes, NK; Mayhew, C; Oakley, O; Phillips, J; Piper, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mayhew, C | 1 |
| Oakley, O | 1 |
| Piper, J | 1 |
| Hughes, NK | 1 |
| Phillips, J | 1 |
| Birch, NJ | 1 |
| Elford, HL | 1 |
| Gallicchio, VS | 1 |
1 other study available for 3,4-dihydroxybenzohydroxamic acid and Disease Exacerbation
| Article | Year |
|---|---|
Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Topics: Animals; Antiviral Agents; Benzamidines; Biomarkers; Didanosine; Disease Progression; Drug Therapy, | 1997 |